Literature DB >> 26549865

A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study.

Emmie Kaljouw1, Bradley R Pieters2, György Kovács3, Peter J Hoskin4.   

Abstract

BACKGROUND AND
PURPOSE: Patients treated with low radiotherapy dose or treated at young age are at a risk of developing local relapse. Although data are preliminary, brachytherapy seems an attractive treatment option for recurrent prostate cancer after previous radiotherapy. Therefore, the UroGEC group of the GEC-ESTRO conducted a Delphi study, to explore expert opinion on the management of salvage prostate brachytherapy.
MATERIAL AND METHODS: For this study, a series of digital questionnaires were sent, which enabled data collection from an international group of experienced participants. Consensus was defined as 80% agreement for each question.
RESULTS: Eighteen experts completed all rounds of the Delphi study. After the final round consensus was reached on 17 out of 38 (45%) questions. Consensus was reached in 52% of questions about patient selection, in 50% of the questions about diagnostic tests and in 22% of the questions on performing salvage prostate brachytherapy.
CONCLUSIONS: The group was able to find consensus on less than half of the questions. Most consensus was reached on topics involving patient selection and diagnostic tests, where participants could build on their experience of daily practice. However, the way to perform the salvage treatment is less established and results in more disagreement between participants.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Delphi study; Prostate neoplasms; Recurrent prostate cancer; Salvage brachytherapy

Mesh:

Substances:

Year:  2015        PMID: 26549865     DOI: 10.1016/j.radonc.2015.10.021

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  4 in total

1.  Salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy.

Authors:  Aurélie Mbeutcha; Laurent Chauveinc; Pierre-Yves Bondiau; Marie-Eve Chand; Matthieu Durand; Daniel Chevallier; Jean Amiel; Daniel Lam Cham Kee; Jean-Michel Hannoun-Lévi
Journal:  Radiat Oncol       Date:  2017-03-09       Impact factor: 3.481

Review 2.  Focal Salvage Treatment of Radiorecurrent Prostate Cancer: A Narrative Review of Current Strategies and Future Perspectives.

Authors:  Marieke van Son; Max Peters; Marinus Moerland; Linda Kerkmeijer; Jan Lagendijk; Jochem van der Voort van Zyp
Journal:  Cancers (Basel)       Date:  2018-12-03       Impact factor: 6.639

3.  Efficacy and toxicity outcomes for patients treated with focal salvage high dose rate brachytherapy for locally recurrent prostate cancer.

Authors:  Finbar Slevin; Samantha Hodgson; Sree Lakshmi Rodda; Peter Bownes; David Bottomley; Ese Adiotomre; Bashar Al-Qaisieh; Emma Dugdale; Oliver Hulson; Joshua Mason; Jonathan Smith; Ann M Henry
Journal:  Clin Transl Radiat Oncol       Date:  2020-03-27

4.  Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review.

Authors:  Jim Zhong; Finbar Slevin; Andrew F Scarsbrook; Maria Serra; Ananya Choudhury; Peter J Hoskin; Sarah Brown; Ann M Henry
Journal:  Front Oncol       Date:  2021-09-09       Impact factor: 6.244

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.